title: [Investigation of gastric cancer chemotherapy in hiroshima prefecture].
abstract: OBJECTIVE
  The Hiroshima Oncology Group of Gastric Cancer(HOG-GC)distributed a multiple-answer questionnaire to investigate the realities of chemotherapy for gastric cancer.
  
  
  METHODS
  Seventy-six hospitals in Hiroshima were surveyed. The Japanese classification was used for the staging criteria.
  
  
  RESULTS
  Forty-one hospitals, including 10 centers for cancer treatment, completed and returned the questionnaires. For stage II & III cases requiring adjuvant chemotherapy, S-1 was the most commonly used(84%)regimen. A standard starting dose was used in 79% of these cases, and S-1 was administered for one year continuously in 84% of the cases. For stage I B & II (T1), S-1 and UFT were used in 45%and 20%of the cases, respectively. In cases with non-resectable gastric cancer, S-1 plus CDDP and S-1 alone were used as a first-line therapy in 62% and 26% of the patients under 75 years age, respectively, and in 33% and 46% of the patients older than 75 years of age, respectively. In patients with ascites and peritoneal dissemination, S-1 plus CDDP, S-1, S-1 plus DTX, S-1 plus PTX, and PTX were used in 26%, 15%, 21%, 17%, and 17% of cases, respectively. Some of the patients with peritoneal dissemination underwent gastrectomy.
  
  
  CONCLUSIONS
  S-1 was widely used for gastric cancer chemotherapy in Hiroshima Prefecture. Taxane-containing regimens or palliative gastrectomy were commonly used in cases with peritoneal dissemination.
authors.affiliation: Dept of Clinical Oncology, Hiroshima Prefectural Hospital.
authors.forename: Masami
authors.initials: M
authors.lastname: Yamauchi
authors.forename: Katsunori
authors.initials: K
authors.lastname: Shinozaki
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Hatanaka
authors.forename: Manabu
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Tanabe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Narahara
authors.forename: Naoki
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: Motoki
authors.initials: M
authors.lastname: Ninomiya
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007564:Japan; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents